# Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy

Source: https://onco.cc/trials/nct05222971/  
OnCo record `nct05222971` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of durvalumab and olaparib in gallbladder cancer and other biliary tract cancers, run by Asan Medical Center, now recruiting.

## Summary

Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy is a phase 2, randomised interventional study registered as NCT05222971 by Asan Medical Center, with a registry enrolment figure of 62 participants, started 2022-04-01 and due to reach its primary completion in 2025-12-30. Interventions recorded: Durvalumab, Olaparib. Conditions listed: Biliary Tract Cancer, DNA Damage Repair Deficiency. Gallbladder cancer is named in the registry entry: "* Histologically confirmed adenocarcinoma of biliary tract (intrahepatic, extrahepatic cholangiocarcinoma, or gallbladder carcinoma).". Sites: South Korea. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: OPTIMUM
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT05222971
- Phase: 2
- Setting: Randomized Open-labeled Phase 2 Study of Maintenance Olaparib With or Without Durvalumab for DDR Gene Mutated Advanced Biliary Tract Cancer Following Platinum-based Chemotherapy
- Sponsor: Asan Medical Center
- Enrolled: 62

## Sources

- ClinicalTrials.gov NCT05222971: https://clinicaltrials.gov/study/NCT05222971

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Olaparib](https://onco.cc/drugs/olaparib/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct05222971.json